Publications

5898 Results

Neuroligin family genes expression associated with first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).

Authors
Zhang W;Shah UH;Yang Y;Millstein J;Soni S;Algaze S;Mittal P;Torres-Gonzalez L;Battaglin F;Mulkerin DL;Ou FS;Venook AP;Innocenti F;Lenz HJ
Journal / Conference
ASCO GI Cancers Symposium (January 8-10, 2026, San Francisco, CA); Poster; Abstract #179
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Colorectal cancer metastatic dMMR Immuno-Therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC): NRG-GI004/SWOG-S1610.

Authors
Lima CMSPR;Yothers G;George TJ;Hochster HS;Sanoff HK;Cohen DJ;Guthrie KA;Jacobs SA;Saeed A;Kopetz S;Colangelo LH;Freeman T;Cole SW;Zuckerman DS;Hong TS;Henry NL;Ganz PA;Blanke CD;Wolmark N;Overman MJ
Journal / Conference
ASCO Gastrointestinal Cancers Symposium (January 8-10, 2026); Oral Abstract #14
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/NRG-GI004

No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404.

Authors
Othus M;Truong TG;Sharon E;Kendra K;Grossman K;Buchbinder E;Khushalani N;Eroglu Z;Chandra S;Doolittle GC;Kirkwood JM;Johnson D;Taylor M;Sondak VK;Ribas A;Patel SP
Journal / Conference
AACR Immuno-Oncology Conference (February 18-21, 2026, Los Angeles, CA); Oral LB-B005
Year
2026
Research Committee(s)
Melanoma
Study Number(s)
S1404

Inflammatory spatial niches distinguished by antigen presentation and interferon response programs explain the high immune response rate of desmoplastic melanoma: Comparison of biopsies from SWOG S1512 and S1616.

Authors
Chen DG;Truong A;Al Deen NN;Gonzalez CR;Baselga-Carretero I;Chen JM;Kendra KL;Eroglu Z;Hu-Lieskovan S;Vanderwalde AM;Wada DA;Plaza JA;Wu MC;Scumpia PO;Ribas A;Campbell KM
Journal / Conference
AACR Immuno-Oncology Conference (February 18-21, 2026, Los Angeles, CA); Abstract B038
Year
2026
Research Committee(s)
Melanoma
Study Number(s)
S1512, S1616

SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).

Authors
Svatek RS;Tangen CM;Meeks JJ;Gilbert SM;Lotan Y;Tyson M;Crispen P;Delacroix SE;Gills J;Daneshmand S;Woods M;Master VA;Mark JR;Alva AS;Bangs R;Nakagawa D;Unger JM;Plets M;Thompson IM;Lerner SP
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); LBA629
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S1602

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.

Authors
Sadeghi S;Callis S;Lara PN;Berg SA;Brown JR;Bangs R;Nakagawa D;Daneshmand S;Murchie I;Flaig TW;Petrylak DP;Lerner SP
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS894
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S1937

SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).

Authors
Ballas LK;Callis S;Daneshmand S;Tripathi A;Hamstra DA;Yu JB;Tyson M;Mouw KW;Meeks JJ;McConkey DJ;Rose KM;Tawagi K;Mittal K;Sachdev S;Flaig TW;Lerner SP
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS913
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S2427

ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).

Authors
Kilari D;Ballman KV;Gelmann EP;Zarrabi KK;Baghaie S;Sumey CJ;Hillman DW;Bryce AH;Rose BS;Nguyen P;Montgomery RB;Berg SA;Tan A;Jacene H;Chen RC;Beltran H;Morris MJ;Galsky MD;Rosenberg JE;McKay RR
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS290
Year
2026
Research Committee(s)
Genitourinary

Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405.

Authors
Soni S;Yang Y;Bartolini M;Mittal P;Ou FS;Torres-Gonzalez L;Shah UH;Lo JH;Soto Trujillo S;Goretsky Y;Zhang W;Venook AP;Algaze S;Millstein J;Lenz HJ
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract 1011
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Differences in survival outcomes among metastatic colorectal cancer patients across fibroblast growth factor receptor 2 and 3 expression levels.

Authors
Trujillo SS;Yang Y;Bartolini M;Soni S;Mittal P;Ou FS;Torres-Gonzalez L;Shah UH;Lo JH;Goretsky Y;Zhang W;Venook A;Algaze S;Millstein J;Lenz HJ
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract 6751
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405